
Photo taken from Joseph Steward/LinkedIn
Apr 19, 2024, 07:31
Joseph Steward: Boston Consulting Group‘s overview of ADCs currently in clinical development
Joseph Steward, Freelance Medical and Scientific Writer, shared on LinkedIn:
“Antibody-drug conjugates (ADCs) have become one of the most promising therapeutic modalities in oncology due to their superior efficacy and favorable side effect profiles relative to standard-of-care chemotherapies. This article from Boston Consulting Group (BCG) provides a great overview of ADCs currently in clinical development for anyone interested. I also included a brief overview of some of their findings below:
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 02:06
Apr 1, 2025, 02:00
Apr 1, 2025, 01:44
Mar 31, 2025, 20:25
Mar 31, 2025, 20:00
Mar 31, 2025, 19:01
Mar 31, 2025, 18:51
Mar 31, 2025, 18:40
Mar 31, 2025, 18:40